Fragile X syndrome: A preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development

Psychopharmacology

Volumn 231, Issue 6, 2014, Pages 1217-1226

  Pop, Andreea S ^a   Gomez Mancilla, Baltazar ^b   Neri, Giovanni ^c   Willemsen, Rob ^a   Gasparini, Fabrizio ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

AFQ056; Dendritic spines; DNA methylation; Epigenetic regulation; FMR1; FMRP; Fragile X syndrome; Mavoglurant; mGluR5; mGluR5 antagonist

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

DNA METHYLATION; DRUG DEVELOPMENT; EPIGENETICS; FMR1 GENE; FRAGILE X SYNDROME; GENE CONTROL; GENE SILENCING; HUMAN; LONG TERM DEPRESSION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84896739499     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3330-3     Document Type: Review

References (120)

1. Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S (1992) Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem 267:13361-13368
2. Abitbol M, Menini C, Delezoide AL, Rhyner T, Vekemans M, Mallet J (1993) Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain. Nat Genet 4:147-153 (Pubitemid 23179098)
3. Bakker CE, Verheij C, Willemsen R, van der Helm R, Erlemans F, Vermey M, Ygrave A, Oogeveen AT, Oostra BA (1994) Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell 78:23-33 (Pubitemid 24228297)
4. Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377 (Pubitemid 38829251)
5. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT (2008) Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 29:293-302
6. Berry-Kravis E, Hessl D, Coffey S et al (2009) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46:266-271
7. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46:94-102
8. Brouwer JR, Willemsen R, Oostra BA (2009) The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet 150B:782-798
9. Brown V, Jin P, Ceman S et al (2001)Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477-487 (Pubitemid 33152783)
10. Burket JA, Herndon AL, Winebarger EE, Jacome LF, Deutsch SI (2011) Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders. Brain Res Bull 86:152-158
11. Chen L, Toth M (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103:1043-1050 (Pubitemid 32289314)
12. Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA (1999) Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 8:2317-2323 (Pubitemid 29525348)
13. Coffee B, Zhang F, Warren ST, Reines D (1999) Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet 22:98-101 (Pubitemid 29214814)
14. Coffee RL Jr, Tessier CR, Woodruff EA 3rd, Broadie K (2010) Fragile X mental retardation protein has a unique, evolutionarily conserved neuronal function not shared with FXR1P or FXR2P. Dis Model Mech 3:471-485
15. Coy JF, Sedlacek Z, Bachner D, Hameister H, Joos S, Lichter P, Delius H, Poustka A (1995) Highly conserved 3′ UTR and expression pattern of FXR1 points to a divergent gene regulation of FXR1 and FMR1. Hum Mol Genet 4:2209-2218
16. Darnell JC, Richter JD (2012) Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb Perspect Biol 4:a012344
17. Darnell JC, Van Driesche SJ, Zhang C et al (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247-261
18. de Diego OY, Severijnen LA, van Cappellen G, Schrier M, Oostra B, Willemsen R (2002) Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol Cell Biol 22:8332-8341 (Pubitemid 35304064)
19. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31:127-132 (Pubitemid 351822560)
20. den Broeder MJ, van der Linde H, Brouwer JR, Oostra BA, Willemsen R, Ketting RF (2009) Generation and characterization of FMR1 knockout zebrafish. PLoS One 4:e7910
21. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL (1993) The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet 4:335-340 (Pubitemid 23231479)
22. Dhami GK, Ferguson SS (2006) Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol Ther 111:260-271 (Pubitemid 43765534)
23. D'Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP (1997) Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76:367-376 (Pubitemid 27008468)
24. D'Hulst C, De GN, Reeve SP, Van DD, De Deyn PP, Hassan BA, Kooy RF (2006) Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 1121:238-245 (Pubitemid 44708899)
25. Dockendorff TC, Su HS, McBride SM, Yang Z, Choi CH, Siwicki KK, Sehgal A, Jongens TA (2002) Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 34:973-984 (Pubitemid 34722286)
26. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF (2007) Correction of fragile X syndrome in mice. Neuron 56:955-962 (Pubitemid 350251119)
27. El IA, Ding XH, Scalia J, Trenkner E, Brown WT, Dobkin C (2005) Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 377:141-146 (Pubitemid 40332346)
28. Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM (1997) Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci 17:1539-1547 (Pubitemid 27089800)
29. Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, Bagni C (2007) The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci 34:343-354 (Pubitemid 46330040)
30. Gantois I, Pop AS, de Esch CE, Buijsen RA, Pooters T, Gomez-Mancilla B, Gasparini F, Oostra BA, D'Hooge R, Willemsen R (2013) Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res 239:72-79
31. Garber KB, Visootsak J, Warren ST (2008) Fragile X syndrome. Eur J Hum Genet 16:666-672 (Pubitemid 351753362)
32. Gasparini F, Lingenhohl K, Stoehr N et al (1999) 2-Methyl-6- (phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38: 1493-1503 (Pubitemid 29457731)
33. Gatto CL, Broadie K (2008) Temporal requirements of the fragile X mental retardation protein in the regulation of synaptic structure. Development 135:2637-2648
34. Giuffrida R, Musumeci S, D'Antoni S, Bonaccorso CM, Giuffrida-Stella AM, Oostra BA, Catania MV (2005) A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci 25:8908-8916 (Pubitemid 41384459)
35. Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ (2010) Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 30:10624-10638
36. Guo W, Allan AM, Zong R et al (2011) Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med 17: 559-565
37. Hinds HL, Ashley CT, Sutcliffe JS, Nelson DL, Warren ST, Housman DE, Schalling M (1993) Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet 3:36-43 (Pubitemid 23063286)
38. Hinton VJ, Brown WT, Wisniewski K, Rudelli RD (1991) Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet 41:289-294
39. Hoeffer CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H, Whelan AM, Zukin RS, Klann E, Tassone F (2012) Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav 11:332-341
40. Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 99:7746-7750 (Pubitemid 34568762)
41. Irwin SA, Galvez R, Greenough WT (2000) Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10:1038-1044
42. Irwin SA, Patel B, Idupulapati M et al (2001) Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet 98:161-167 (Pubitemid 32051804)
43. Jacquemont S, Curie A, des Portes V et al (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3:64ra1
44. Kanellopoulos AK, Semelidou O, Kotini AG, Anezaki M, Skoulakis EM (2012) Learning andmemory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in Drosophila . J Neurosci 32:13111-13124
45. Kao DI, Aldridge GM, Weiler IJ, Greenough WT (2010) Altered mRNA transport, docking, and protein translation in neurons lacking fragile X mental retardation protein. Proc Natl Acad Sci U S A 107:15601-15606
46. Khandjian EW, Fortin A, Thibodeau A, Tremblay S, Cote F, Devys D, Mandel JL, Rousseau F (1995) A heterogeneous set of FMR1 proteins is widely distributed in mouse tissues and is modulated in cell culture. Hum Mol Genet 4:783-789
47. Krueger DD, Osterweil EK, Chen SP, Tye LD, Bear MF (2011) Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A 108:2587-2592
48. Kumari D, Usdin K (2001) Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter. Implications for fragile X mental retardation syndrome. J Biol Chem 276:4357-4364
49. Kwan KY, Lam MM, Johnson MB et al (2012) Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell 149:899-911
50. Levenga J, de Vrij FM, Oostra BA, Willemsen R (2010) Potential therapeutic interventions for fragile X syndrome. Trends Mol Med 16:516-527
51. Lindsley CW, Emmitte KA (2009) Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 12:446-457
52. Lubs HA (1969) A marker X chromosome. Am J Hum Genet 21:231-244
53. Lujan R, Nusser Z, Roberts JD, Shigemoto R, Somogyi P (1996) Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci 8:1488-1500
54. Malter HE, Iber JC, Willemsen R, de Graaff E, Tarleton JC, Leisti J, Warren ST, Oostra BA (1997) Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet 15:165-169 (Pubitemid 27061635)
55. Martin JP, Bell J (1943) A pedigree ofmental defect showing sex-linkage. J Neurol Psychiatry 6:154-157
56. McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, Strupp BJ (2008) Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav Neurosci 122:293-300 (Pubitemid 351672321)
57. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L (2012) Chronic pharmacological mGlu5 inhibition corrects fragile Xin adultmice. Neuron 74: 49-56
58. Mientjes EJ, Nieuwenhuizen I, Kirkpatrick L, Zu T, Hoogeveen- Westerveld M, Severijnen L, Rife M, Willemsen R, Nelson DL, Oostra BA (2006) The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis 21: 549-555 (Pubitemid 43277538)
59. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, Bauchwitz RP (2009) Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 56:463-472
60. Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE (2002) Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12:39-46 (Pubitemid 34211245)
61. Mouse Genome Database (2012) Mouse Genome Informatics Website. The Jackson Laboratory, Bar Harbor, Maine
62. Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW, Murphy DL, D'Ercole AJ, Crawley JN, Magnuson TR, Lauder JM (2009) Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav 8:129-142
63. Naumann A, Hochstein N, Weber S, Fanning E, Doerfler W (2009) A distinct DNA-methylation boundary in the 5′-upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet 85:606-616
64. Nielsen DM, Derber WJ, McClellan DA, Crnic LS (2002) Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res 927:8-17 (Pubitemid 34114044)
65. Nosyreva ED, Huber KM (2006) Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 95:3291-3295
66. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF, Mandel JL (1991) Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252:1097-1102 (Pubitemid 21917021)
67. Oostra BA, Nelson DL (2006) Animal models of fragile X syndrome: mice and flies. In:Wells BD, Ashizawa T (eds) Genetic instabilities and neurological diseases. Elsevier, Amsterdam, pp 175-193
68. Pagano A, Ruegg D, Litschig S et al (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b] chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758
69. Pan L, Zhang YQ, Woodruff E, Broadie K (2004) The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. Curr Biol 14:1863-1870 (Pubitemid 39408777)
70. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST (1999) Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94:185-192 (Pubitemid 29457608)
71. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T (1982) Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 2:129-133 (Pubitemid 12025672)
72. Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL (2000) (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9:1145-1159 (Pubitemid 30248600)
73. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:817-822 (Pubitemid 121001715)
74. Pietropaolo S, Guilleminot A, Martin B, D'Amato FR, Crusio WE (2011) Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice. PLoS One 6:e17073
75. Portera-Cailliau C (2012) Which comes first in fragile X syndrome, dendritic spine dysgenesis or defects in circuit plasticity? Neuroscientist 18:28-44
76. Reiss AL, Abrams MT, Greenlaw R, Freund L, Denckla MB (1995) Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat Med 1:159-167
77. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, Bagni C, Ammassari-Teule M (2005) Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A 102:11557-11562 (Pubitemid 41153858)
78. Rocher JP, Bonnet B, Bolea C, Lutjens R, Le PE, Poli S, Epping-Jordan M, Bessis AS, Ludwig B, Mutel V (2011) mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. Curr Top Med Chem 11:680-695
79. Ronesi JA, Huber KM (2008) Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. Sci Signal 1:e6
80. Rudelli RD, Brown WT, Wisniewski K, Jenkins EC, Laure- Kamionowska M, Connell F, Wisniewski HM (1985) Adult fragile X syndrome. Clinico- neuropathologic findings. Acta Neuropathol 67:289-295 (Pubitemid 15040840)
81. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, Hessl D (2012) Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 42:1377-1392
82. Schapiro MB, Murphy DG, Hagerman RJ et al (1995) Adult fragile X syndrome: neuropsychology, brain anatomy, and metabolism. Am J Med Genet 60:480-493 (Pubitemid 26002115)
83. Schutt J, Falley K, Richter D, Kreienkamp HJ, Kindler S (2009) Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem 284: 25479-25487
84. Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, Loring JF, Haggarty SJ (2011) Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cellmodels of fragile X syndrome. PLoS One 6:e26203
85. Sherman S (2012) Epidemiology. In: Hagerman RJ, Hagerman PJ (eds) Fragile X syndrome: diagnosis, treatment and research. The Johns Hopkins University Press, Balitmore, pp 136-168
86. Siomi MC, Siomi H, Sauer WH, Srinivasan S, Nussbaum RL, Dreyfuss G (1995) FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J 14:2401-2408
87. Smeets HJ, Smits AP, Verheij CE, Theelen JP, Willemsen R, van de Burgt I, Hoogeveen AT, Oosterwijk JC, Oostra BA (1995) Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet 4:2103-2108
88. Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R (2005) Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 4:420-430 (Pubitemid 41428518)
89. Spencer CM, Alekseyenko O, Hamilton SM, Thomas AM, Serysheva E, Yuva-Paylor LA, Paylor R (2011)Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res 4:40-56
90. Stöger R, Genereux DP, Hagerman RJ, Hagerman PJ, Tassone F, Laird CD (2011) Testing the FMR1 promoter for mosaicism in DNA methylation among CpG sites, strands, and cells in FMR1-expressing males with fragile X syndrome. PLoS One 6:e23648
91. Su T, Fan HX, Jiang T, Sun WW, Den WY, Gao MM, Chen SQ, Zhao QH, Yi YH (2011) Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology (Berlin) 215:291-300
92. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, Warren ST (1992) DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1:397-400
93. Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G (2005) Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 13:641-648 (Pubitemid 40691406)
94. Tabolacci E, De Pascalis I, Accadia M, Terracciano A, Moscato U, Chiurazzi P, Neri G (2008a) Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics 18: 738-741
95. Tabolacci E, Moscato U, Zalfa F, Bagni C, Chiurazzi P, Neri G (2008b) Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet 16:1487-1498
96. Tabolacci E, Pirozzi F, Gomez-Mancilla B, Gasparini F, Neri G (2012) The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Med Genet 13:13
97. Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ (2000) Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet 94:232-236
98. Tassone F, Beilina A, Carosi C, Albertosi S, Bagni C, Li L, Glover K, Bentley D, Hagerman PJ (2007) Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 13: 555-562 (Pubitemid 46506938)
99. Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R (2012) Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berlin) 219:47-58
100. Till SM, Wijetunge LS, Seidel VG, Harlow E, Wright AK, Bagni C, Contractor A, Gillingwater TH, Kind PC (2012) Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome. Hum Mol Genet 21:2143-2156
101. Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, Hutchison JA, Di Raimo FR, Tabolacci E, Neri G (2010) Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A 152A:1420-1427
102. Tranfaglia MR (2011) The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci 33:337-348
103. Tucker B, Richards R, Lardelli M (2004) Expression of three zebrafish orthologs of human FMR1-related genes and their phylogenetic relationships. Dev Genes Evol 214:567-574 (Pubitemid 39496785)
104. Tucker B, Richards RI, Lardelli M (2006) Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet 15:3446-3458 (Pubitemid 44811597)
105. Turner G, Robinson H, Laing S, van den Berk M, Colley A, Goddard A, Sherman S, Partington M (1992) Population screening for fragile X. Lancet 339:1210-1213
106. van't Padje S, Engels B, Blonden L, Severijnen LA, Verheijen F, Oostra BA, Willemsen R (2005) Characterisation of Fmrp in zebrafish: evolutionary dynamics of the fmr1 gene. Dev Genes Evol 215: 198-206 (Pubitemid 40552953)
107. Varney MA, Cosford ND, Jachec C et al (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 290:170-181 (Pubitemid 29302317)
108. Verkerk AJ, Pieretti M, Sutcliffe JS et al (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914 (Pubitemid 121001321)
109. Vinueza Veloz MF, Buijsen RA, Willemsen R, Cupido A, Bosman LW, Koekkoek SK, Potters JW, Oostra BA, De Zeeuw CI (2012) The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav 11:325-331
110. Wang X, Snape M, Klann E, Stone JG, Singh A, Petersen RB, Castellani RJ, Casadesus G, Smith MA, Zhu X (2012) Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome. J Neurochem 121:672-679
111. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, Comery TA, Patel B, Eberwine J, Greenough WT (1997) Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A 94:5395-5400 (Pubitemid 27214794)
112. Willemsen R, Bontekoe C, Tamanini F, Galjaard H, Hoogeveen A, Oostra B (1996) Association of FMRP with ribosomal precursor particles in the nucleolus. Biochem Biophys Res Commun 225:27-33 (Pubitemid 26285392)
113. Willemsen R, Bontekoe CJ, Severijnen LA, Oostra BA (2002) Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet 110:601-605 (Pubitemid 36075010)
114. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053-1066 (Pubitemid 41503304)
115. Yu S, Pritchard M, Kremer E et al (1991) Fragile X genotype characterized by an unstable region of DNA. Science 252:1179-1181 (Pubitemid 21917032)
116. Zalfa F, Giorgi M, Primerano B, Moro A, di Penta A, Reis S, Oostra B, Bagni C (2003) The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 112:317-327 (Pubitemid 36183653)
117. Zalfa F, Eleuteri B, Dickson KS et al (2007) A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci 10:578-587 (Pubitemid 46652449)
118. Zang JB, Nosyreva ED, Spencer CM et al (2009) A mouse model of the human fragile X syndrome I304N mutation. PLoS Genet 5: e1000758
119. Zhang Y, O'Connor JP, Siomi MC, Srinivasan S, Dutra A, Nussbaum RL, Dreyfuss G (1995) The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J 14:5358-5366
120. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K (2001) Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 107:591-603 (Pubitemid 34014861)